Nestlé continues to expand its presence in the world of medicine, announcing a deal to acquire milk-allergy testing firm DBV Technologies.
The deal will see the Swiss giant pay €10m immediately for rights to DBV’s skin patch test (for cow’s milk protein allergy, or CMPA), with up to €90m more payable later depending on successful development of the test. The acquisition will be conducted by Nestle’s Health Science division.
Nestlé noted: “This innovation can become the breakthrough diagnostic for CMPA”. The allergy affects up 3% of all toddlers, but many others are falsely diagnosed as they report similar symptoms. The test requires clinical trials before being approved for sale, and is expected to be submitted to regulators by 2021.